<DOC>
	<DOCNO>NCT02225587</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity sequential administration Prevnar 13™ Pneumovax™ 23 healthy participant 50 year age old . The primary hypothesis study 1 ) geometric mean titer ( GMTs ) pneumococcal serotypes 22F 33F ( serotypes Pneumovax™ 23 Prevnar 13™ ) measure Week 12 superior participant administer Prevnar 13™ Day 1 Pneumovax™ 23 Week 8 , compare participant administer Prevnar 13™ Day 1 placebo Week 8 2 ) GMTs pneumococcal serotypes share two vaccine measure Week 12 non-inferior participant administer Prevnar 13™ follow Pneumovax™ 23 compare participant administer Prevnar 13™ follow placebo .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Sequential Administration Prevnar 13™ Pneumovax™ 23 Healthy Participants 50 Years Age Older ( V110-029 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Any chronic illness must document stable condition Male , female agrees remain abstinent use 2 acceptable method contraception 6 week receive study vaccination , female reproductive potential Is immediate family member investigational site sponsor staff directly involve trial Prior administration pneumococcal vaccine History invasive pneumococcal disease Known hypersensitivity component pneumococcal polysaccharide vaccine , pneumococcal conjugate vaccine , diphtheria toxoidcontaining vaccine Known suspect impairment immunological function , document Human Immunodeficiency Virus ( HIV ) infection , asplenia , history autoimmune disease Received systemic corticosteroid ( equivalent &gt; =2 mg/kg total daily dose prednisone &gt; =20 mg/kg person weigh &gt; 10 kg ) &gt; =14 consecutive day complete treatment &lt; =30 day study vaccination , receive systemic corticosteroid exceed physiological dos ( ~5 mg/day prednisone equivalent ) within 14 day study vaccination ( topical , ophthalmic , intraarticular , inhaled/nebulized steroid permit ) . Has coagulation disorder contraindicate intramuscular vaccination Receiving immunosuppressive therapy , include chemotherapeutic agent use treat cancer condition , treatment associate organ bone marrow transplantation autoimmune disease Received blood transfusion blood product , include immunoglobulin &lt; =6 month receive study vaccine , schedule receive within 30 day Participated another clinical study investigational product &lt; =2 week current study Is breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>